BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures (FIAS)

• ClinicalTrials.gov Identifier: NCT03474770
• Recruitment Status: Unknown
• First Posted: March 23, 2018
• Last Update Posted: March 23, 2018
• Sponsor: Supernus Pharmaceuticals, Inc.
• Collaborator: Biscayne Neurotherapeutics Australia Pty, Ltd.
• Information provided by (Responsible Party): Supernus Pharmaceuticals, Inc.

Study Description

Brief Summary:

The purpose of this study is to examine safety signals and demonstrate seizure reduction in adults with FIAS treated with BIS-001ER as an add-on therapy in an in-patient and out-patient study design.

Condition or disease	Intervention/treatment	Phase
Focal Impaired Awareness Seizures	Drug: BIS-001ER	Phase 1; Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 16 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Evaluation of Safety and Efficacy of BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures
• Estimated Study Start Date: April 2, 2018
• Estimated Primary Completion Date: November 30, 2018
• Estimated Study Completion Date: November 30, 2018

Arms and Interventions

Arm

Intervention/treatment

Experimental: BIS-001ER; Dose administration for each participant will begin at 0.25mg b.i.d. escalating sequentially every 4 days to a maximum tolerated dose or target dose of 1.75mg b.i.d. Upon reaching the target dose or maximum tolerated dose, participants will maintain that dose for the balance of the 1 month out-patient titration period, after which they will begin a 96-hour in-patient video EEG monitoring treatment period.

Drug: BIS-001ER; BIS-001 ER is an extended release formulation of the nutritional supplement Huperzine A.; Other Name: Huperzine A ER

Outcome Measures

Primary Outcome Measures :

1. Effect of BIS-001ER on Seizure Count [ Time Frame: 6 Weeks ]
   Reduction in average daily seizure count between baseline (pre-treatment) and evaluation (on treatment) video EEG monitoring periods.

Secondary Outcome Measures :

1. Effect of BIS-001ER on Percent Reduction in Daily Seizure Count [ Time Frame: 6 Weeks ]
   Percent reduction in average daily seizure count from the baseline VEM period compared to the evaluation video EEG monitoring period (on treatment).
2. Effect of BIS-001ER on Seizure Count vs Titration Period (Diary) [ Time Frame: 6 Weeks ]
   Percent reduction in average number of seizures from the baseline period. (screening/retrospective diary) compared to the last week of the titration treatment period.
3. Percent of Treatment Responders [ Time Frame: 6 Weeks ]
   Percent of participants considered treatment responders defined as those with a ≥25%, ≥50%, ≥75% reduction in seizures from the baseline VEM period compared to the VEM treatment evaluation period.
4. Effect of BIS-001ER on Seizure Count During Extension Phase [ Time Frame: 12 Months ]
   Percent reduction of average number of seizures vs. baseline/retrospective diary at 1, 3, 6, 12 months during the extension period.
5. Complete Seizure Protection [ Time Frame: 6 Weeks ]
   Proportion of subjects with 100% seizure reduction.
6. Need for Rescue Medication [ Time Frame: 6 Weeks ]
   Proportion of subjects requiring rescue medication at different dosages.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Speak English with sufficient proficiency to read and comprehend the Informed Consent document, and to communicate with study staff.
• Be able to consent to participate by signing the Informed Consent document after a full explanation of the nature and purpose of this study.
• Have signed the Informed Consent before any study-specific procedures are performed.
• Be males or females between 18 - 65 years of age.
• Have a diagnosis of FIAS type epilepsy with or without additional focal aware or non-aware seizures with generalization.
• Have a current minimum average of 5 countable seizures / week to enroll in study.
• Have at least 5 focal impaired awareness seizures during the 96-hour baseline VEM period.
• Be receiving stable doses (for at least 4 weeks) of one to four currently marketed anti-epileptic drugs (AEDs), with or without vagus nerve stimulation (in which case the patient should be on the same stimulation parameters for at least 4 weeks).
• Have a negative urinary pregnancy test upon admission to the site on Day 1.
• Be in good general health in the judgment of the Principal Investigator based upon medical history, physical examination, standard 12-lead ECG, and clinical laboratory evaluations obtained within the two weeks prior to enrollment.
• Be able to comply with all study-specified procedures.
• Weight between 40 and 120 kg.

Exclusion Criteria:

• Has taken Huperzine A within the past year.
• Is planning to become pregnant or impregnate spouse, not using an acceptable method of birth control (defined as use of double-barrier birth control methods, use of oral contraceptives, or surgical sterilization), pregnant or nursing.
• Have non-epileptic events that could be confused by the patient and/or study staff as epileptic seizures.
• Has seizures that are difficult to count; for example, seizure clusters defined as multiple seizures with at least one seizure within 30 minutes of the previous seizure.
• Have less than the 5 minimum accepted seizures required during baseline evaluation period screen.
• Have a history of only seizure clusters, for example, seizure clusters defined as multiple seizures with at least one seizure within 30 minutes of the previous seizure.
• Has attempted suicide within the past 2 years.
• Has a history of status epilepticus in the 6 months previous to enrollment.
• Has a pre-existing medical condition (including an existing progressive or degenerative neurological disorder including brain tumor, active encephalitis, active meningitis or abscess) or takes medications that, in the Principal Investigator's opinion, could interfere with the participant's suitability for participation in the study.
• Has a history or evidence of significant psychiatric disturbance or illness, including alcohol or drug abuse within the past 2 years, or symptoms of psychosis (hallucinations, delusions) in the last 5 years.
• Has had any clinical laboratory abnormalities within the past two months, prior to screening, considered of clinical significance by the Principal Investigator.
• Is on concomitant therapy with non-AEDs that are cholinergic.
• Has participated in any clinical investigational drug or device study within four weeks prior to study entry.
• Inability to complete seizure diary.
• Is currently taking or has taken Epigallocatechin gallate (EGCG) within the past 14 days, or consume foods or drinks containing EGCG; including green, white, oolong teas and certain black teas, or food containing >100grams of carob powder within the past 14 days.

Contacts and Locations

Contacts

Contact: Joshua T Johnstone, PhD; 786-502-4224; josh@biscayneneuro.com

Contact: Peter Goldstein, MS; 786-502-4223; peter@biscayneneuro.com

Locations

Australia, Victoria

The Alfred Hospital; Recruiting

Melbourne, Victoria, Australia, 3050

Contact: Jack Germaine +61 03 9076 2029 j.germaine@alfred.org.au

Principal Investigator: Terence O'Brien, MD

The Royal Melbourne Hospital; Recruiting

Melbourne, Victoria, Australia, 3050

Contact: Darren Germaine, RN +61 03 9342 7879 darren.germaine@mh.org.au

Principal Investigator: Patrick Kwan, PhD, MB Bchir

Sponsors and Collaborators

Supernus Pharmaceuticals, Inc.

Biscayne Neurotherapeutics Australia Pty, Ltd.

Investigators

• Study Chair: Stephen D Collins, MD, PhD; Supernus Pharmaceuticals, Inc.

More Information

• Responsible Party: Supernus Pharmaceuticals, Inc.
• ClinicalTrials.gov Identifier: NCT03474770
• Other Study ID Numbers: BNI-02-1b
• First Posted: March 23, 2018
• Last Update Posted: March 23, 2018
• Last Verified: March 2018

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Seizures; Neurologic Manifestations; Nervous System Diseases; Huperzine A; Cholinesterase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action; Cholinergic Agents; Neurotransmitter Agents; Physiological Effects of Drugs; Neuroprotective Agents; Protective Agents